Key facts
- This page summarizes Mr. Mark Nelson's Form 3 filing for Telix Pharmaceuticals Ltd (TLX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2026, 07:24.
Mr. Mark Nelson - 18 Mar 2026 Form 3 Insider Report for Telix Pharmaceuticals Ltd (TLX)
- Reporting relationship
- Director
- Issuer ticker
- TLX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Oliver Newman, on behalf of Mr. Mark Nelson
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Mr. Mark Nelson filed Form 3 for Telix Pharmaceuticals Ltd (TLX) on 01 Apr 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001352919
Primary reporting owner
Nelson Mark Alexander
- Relationship
- Director
- Address
- C/O TELIX PHARMACEUTICALS LTD, 55 FLEMINGTON RD, NORTH MELBOURNE, AUSTRALIA
- Signature
- /s/ Oliver Newman, on behalf of Mr. Mark Nelson
- Signature date
- 01 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,628,750
- Date
- 18 Mar 2026
- Ownership
- MAN Holdings Pty Ltd
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
MAN Holdings Pty Ltd, as Trustee for the Nelson Hybrid Trust, of which Mr. Nelson is a director and shareholder.
SEC remarks
Ex. 24 - Power of Attorney